The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences
Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Arjun V. Balar
Leadership - GT Biopharma; GT Biopharma; GT Biopharma; GT Biopharma
Stock and Other Ownership Interests - GT Biopharma; GT Biopharma; GT Biopharma; GT Biopharma
Honoraria - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Merck; Merck; Merck; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bristol-Myers Squibb/Celgene; Bristol-Myers Squibb/Celgene; Bristol-Myers Squibb/Celgene; Bristol-Myers Squibb/Celgene; Cerulean Pharma; Cerulean Pharma; Cerulean Pharma; Cerulean Pharma; Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Incyte; Incyte; Incyte; Incyte; Merck; Merck; Merck; Merck; Nektar; Nektar; Nektar; Nektar; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Seagen; Seagen; Seagen; Seagen
 
Daniel P. Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Exelixis; Exelixis; Exelixis; Exelixis; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Incyte; Incyte; Incyte; Incyte; Ipsen; Ipsen; Ipsen; Ipsen; Janssen; Janssen; Janssen; Janssen; Lilly; Lilly; Lilly; Lilly; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Regeneron; Regeneron; Regeneron; Regeneron; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen; Urogen pharma; Urogen pharma; Urogen pharma; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Replimune (Inst); Replimune (Inst); Replimune (Inst); Replimune (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Expert Testimony - Celgene; Celgene; Celgene; Celgene; sanofi; sanofi; sanofi; sanofi
 
Arash Rezazadeh
Stock and Other Ownership Interests - ECOM Medical; ECOM Medical; ECOM Medical; ECOM Medical
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Genentech; Genentech; Genentech; Genentech; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer
Speakers' Bureau - Amgen; Amgen; Amgen; Amgen; Astellas Medivation; Astellas Medivation; Astellas Medivation; Astellas Medivation; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AVEO; AVEO; AVEO; AVEO; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Genentech; Genentech; Genentech; Genentech; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Janssen; Janssen; Janssen; Janssen; Merck; Merck; Merck; Merck; Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi; Seagen; Seagen; Seagen; Seagen
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Arvinas (Inst); Arvinas (Inst); Arvinas (Inst); Arvinas (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bavarian Nordic (Inst); Bavarian Nordic (Inst); Bavarian Nordic (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); BeyondSpring Pharmaceuticals (Inst); BeyondSpring Pharmaceuticals (Inst); BeyondSpring Pharmaceuticals (Inst); BioClin Therapeutics (Inst); BioClin Therapeutics (Inst); BioClin Therapeutics (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Epizyme (Inst); Epizyme (Inst); Epizyme (Inst); Epizyme (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); MacroGenics (Inst); MacroGenics (Inst); MacroGenics (Inst); MacroGenics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Medivation; Astellas Medivation; Astellas Medivation; Astellas Medivation; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Genentech; Genentech; Genentech; Genentech; Janssen; Janssen; Janssen; Janssen; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Prometheus; Prometheus; Prometheus; Prometheus
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Janssen; Janssen; Janssen; Janssen; Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Loxo/Lilly; Loxo/Lilly; Loxo/Lilly; Loxo/Lilly; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); BMS (Inst); BMS (Inst); BMS (Inst); BMS (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen
 
Aude Flechon
Honoraria - AAA HealthCare; AAA HealthCare; AAA HealthCare; AAA HealthCare; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; BMS; BMS; BMS; BMS; Ipsen; Ipsen; Ipsen; Ipsen; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; PFIZER; PFIZER; PFIZER; PFIZER; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis
Travel, Accommodations, Expenses - AAA HealthCare; AAA HealthCare; AAA HealthCare; AAA HealthCare; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; BMS; BMS; BMS; BMS; IPSEN; IPSEN; IPSEN; IPSEN; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Pfizer; Pfizer; Pfizer; Pfizer; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis
 
Rohit K. Jain
Honoraria - Curio Science; Curio Science; Curio Science; Curio Science; DAVA Oncology; DAVA Oncology; DAVA Oncology; DAVA Oncology; NCCN/Pfizer; NCCN/Pfizer; NCCN/Pfizer; NCCN/Pfizer; OncLive/MJH Life Sciences; OncLive/MJH Life Sciences; OncLive/MJH Life Sciences; OncLive/MJH Life Sciences
Consulting or Advisory Role - AVEO; AVEO; AVEO; AVEO; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Pfizer; Pfizer; Pfizer; Pfizer; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Speakers' Bureau - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Seagen; Seagen; Seagen; Seagen; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Research Funding - Bristol Myers Squibb; Bristol Myers Squibb; Bristol Myers Squibb; Bristol Myers Squibb; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; NCI; NCI; NCI; NCI
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AVEO; AVEO; AVEO; AVEO; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Genentech; Genentech; Genentech; Genentech; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Medivation/Astellas; Medivation/Astellas; Medivation/Astellas; Medivation/Astellas; MEI Pharma; MEI Pharma; MEI Pharma; MEI Pharma; Merck; Merck; Merck; Merck; Nektar; Nektar; Nektar; Nektar; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Seagen; Seagen; Seagen; Seagen
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Arvinas (Inst); Arvinas (Inst); Arvinas (Inst); Arvinas (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Manojkumar Bupathi
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Pfizer; Pfizer; Pfizer; Pfizer
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis
Speakers' Bureau - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Pfizer; Pfizer; Pfizer; Pfizer
 
Philippe Barthelemy
Honoraria - Astellas Oncology; Astellas Oncology; Astellas Oncology; Astellas Oncology; BMS Brazil; BMS Brazil; BMS Brazil; BMS Brazil; Incyte; Incyte; Incyte; Incyte; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Merck; Merck; Merck; Merck; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Pfizer; Pfizer; Pfizer; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer; Pfizer; Pfizer; Pfizer
 
Philippe Beuzeboc
No Relationships to Disclose
 
Phillip Lee Palmbos
Research Funding - Immunomedics; Immunomedics; Immunomedics; Immunomedics; Roche; Roche; Roche; Roche
 
Christos Kyriakopoulos
Stock and Other Ownership Interests - Biogen; Biogen; Biogen; Biogen; Epic Systems (I); Epic Systems (I); Epic Systems (I); Epic Systems (I)
Consulting or Advisory Role - AVEO; AVEO; AVEO; AVEO; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Sanofi; Sanofi; Sanofi; Sanofi
Research Funding - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; ESSA; ESSA; ESSA; ESSA; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Pionyr; Pionyr; Pionyr; Pionyr; Sanofi; Sanofi; Sanofi; Sanofi
 
Damien Pouessel
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Ipsen; Ipsen; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Merck; Merck; Merck; Merck
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Pfizer; Pfizer; Pfizer; Pfizer
 
Cora N. Sternberg
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Genzyme; Genzyme; Genzyme; Genzyme; Immunomedics; Immunomedics; Immunomedics; Immunomedics; IMPAC Medical Systems; IMPAC Medical Systems; IMPAC Medical Systems; IMPAC Medical Systems; Incyte; Incyte; Incyte; Incyte; Medscape; Medscape; Medscape; Medscape; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; UroToday; UroToday; UroToday; UroToday
 
Julia Tonelli
No Relationships to Disclose
 
Mitch Sierecki
Employment - Bayer; Bayer; Bayer; Bayer; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
Stock and Other Ownership Interests - Bayer; Bayer; Bayer; Bayer; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
 
Huafeng Zhou
Employment - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; 4D Pharma; 4D Pharma; 4D Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BostonGene; BostonGene; BostonGene; BostonGene; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Dyania Health; Dyania Health; Dyania Health; Dyania Health; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Fresenius Kabi; Fresenius Kabi; Fresenius Kabi; Fresenius Kabi; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; Genentech; Genentech; Genentech; Genentech; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Guardant Health; Guardant Health; Guardant Health; Guardant Health; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Janssen; Janssen; Janssen; Janssen; Lucence; Lucence; Lucence; Lucence; Merck; Merck; Merck; Merck; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Pfizer; Pfizer; Pfizer; Pfizer; PureTech; PureTech; PureTech; PureTech; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Regeneron; Regeneron; Regeneron; Regeneron; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen; Silverback Therapeutics; Silverback Therapeutics; Silverback Therapeutics; Silverback Therapeutics; Urogen pharma; Urogen pharma; Urogen pharma; Urogen pharma
Research Funding - Bavarian Nordic (Inst); Bavarian Nordic (Inst); Bavarian Nordic (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst)